Treatment of X-Linked Alport Syndrome in Female Patients

This protocol addresses female patients with X-linked Alport syndrome — a sub-population in whom clinically significant renal disease can develop and in whom nephroprotective intervention is specifically indicated.

Females with X-linked Alport syndrome can present with hypertension, proteinuria, and other risk factors associated with renal failure progression. Renin-angiotensin system (RAS) antagonists are nephroprotective in this group and are indicated when these clinical features are present.

The regimen for this scenario involves renin-angiotensin system (RAS) antagonist therapy, with defined criteria governing patient selection and the timing of initiation — including consideration of whether to act before specific clinical markers have appeared.

Full initiation criteria, patient selection details, and monitoring approach are in the complete structured protocol.